Design of Improved Oncolytic Adenoviruses

Advances in Cancer Research

Volumn 115, Issue , 2012, Pages 93-114

  Alemany, Ramon ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Oncolytic adenovirus; Stroma barrier; Virotherapy

Indexed keywords

CG 7870; COLLAGEN; COMPLEMENT COMPONENT C3B RECEPTOR; FC RECEPTOR; FIBRIN; FIBRONECTIN; GLYCOSAMINOGLYCAN; INTEGRIN; LAMININ; LONTUCIREV; ONCOLYTIC ADENOVIRUS; OSTEONECTIN; POLYMER; PROTEOGLYCAN; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG; ONCOLYTIC VIRUS; TUMOR ANTIGEN; VIRUS DNA;

ADENOVIRUS 5; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONNECTIVE TISSUE; DRUG BINDING; ERYTHROCYTE; FLU LIKE SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; KUPFFER CELL; MONOCYTE; NAUSEA; NEUTROPHIL; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PRIORITY JOURNAL; THROMBOCYTE; TUMOR IMMUNITY; VIROTHERAPY; VIRUS CAPSID; ADENOVIRUS; ANIMAL; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; IMMUNE SYSTEM; METABOLISM; METHODOLOGY; MUTATION; NEOPLASM; ONCOLYTIC VIROTHERAPY; PROMOTER REGION; REVIEW;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; DNA, VIRAL; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNE SYSTEM; MUTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC;

EID: 84866787847     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398342-8.00004-5     Document Type: Chapter

References (66)

1. Ahmed A.U., Tyler M.A., Thaci B., Alexiades N.G., Han Y., Ulasov I.V., et al. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Molecular Pharmaceutics 2011, 8:1559-1572.
2. Alcayaga-Miranda F., Cascallo M., Rojas J.J., Pastor J., Alemany R. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Therapy 2010, 17:792-802.
3. Alemany R., Cascallo M. Oncolytic adenoviruses from the perspective of the immune system. Future Microbiology 2009, 4:527-536.
4. Alemany R., Curiel D.T. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Therapy 2001, 8:1347-1353.
5. Alemany R., Suzuki K., Curiel D.T. Blood clearance rates of adenovirus type 5 in mice. Journal of General Virology 2000, 81(Pt 11):2605-2609.
6. Bassi E.J., Aita C.A., Camara N.O. Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand?. World Journal of Stem Cells 2011, 3:1-8.
7. Bayer W., Tenbusch M., Lietz R., Johrden L., Schimmer S., Uberla K., et al. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. Journal of Virology 2010, 84:1967-1976.
8. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373-376.
9. Bortolanza S., Bunuales M., Otano I., Gonzalez-Aseguinolaza G., Ortiz-de-Solorzano C., Perez D., et al. Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Molecular Therapy 2009, 17:614-622.
10. Breitbach C.J., Burke J., Jonker D., Stephenson J., Haas A.R., Chow L.Q., et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477:99-102.
11. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Molecular Therapy 2007, 15:1686-1693.
12. Cerullo V., Pesonen S., Diaconu I., Escutenaire S., Arstila P.T., Ugolini M., et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Research 2010, 70:4297-4309.
13. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331:1559-1564.
14. Cheng J., Sauthoff H., Huang Y., Kutler D.I., Bajwa S., Rom W.N., et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Molecular Therapy 2007, 15:1982-1990.
15. Choi I.K., Lee Y.S., Yoo J.Y., Yoon A.R., Kim H., Kim D.S., et al. Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy. Gene Therapy 2010, 17:190-201.
16. Choi J.W., Lee J.S., Kim S.W., Yun C.O. Evolution of oncolytic adenovirus for cancer treatment. Advanced Drug Delivery Reviews 2012, 64:720-729.
17. Coughlan L., Alba R., Parker A.L., Bradshaw A.C., McNeish I.A., Nicklin S.A., et al. Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2011, 2:2290-2355.
18. Crompton J., Toogood C.I., Wallis N., Hay R.T. Expression of a foreign epitope on the surface of the adenovirus hexon. Journal of General Virology 1994, 75:133-139.
19. Dias J.D., Hemminki O., Diaconu I., Hirvinen M., Bonetti A., Guse K., et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Therapy 2011, (10 November, 2011). 10.1038/gt.2011.176.
20. Fang J., Nakamura H., Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews 2011, 63:136-151.
21. Fernandes M.S., Gomes E.M., Butcher L.D., Hernandez-Alcoceba R., Chang D., Kansopon J., et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clinical Cancer Research 2009, 15:4847-4856.
22. Ganesan L.P., Mohanty S., Kim J., Clark K.R., Robinson J.M., Anderson C.L. Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathogens 2011, 7. e1002281.
23. Ganesh S., Gonzalez Edick M., Idamakanti N., Abramova M., Vanroey M., Robinson M., et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Research 2007, 67:4399-4407.
24. Ganesh S., Gonzalez-Edick M., Gibbons D., Van Roey M., Jooss K. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Clinical Cancer Research 2008, 14:3933-3941.
25. Garcia-Castro J., Alemany R., Cascallo M., Martinez-Quintanilla J., Arriero Mdel M., Lassaletta A., et al. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: An exploratory study. Cancer Gene Therapy 2010, 17:476-483.
26. Garcia-Castro J., Martinez-Palacio J., Lillo R., Garcia-Sanchez F., Alemany R., Madero L., et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Therapy 2005, 12:341-349.
27. Gimenez-Alejandre M., Cascallo M., Bayo-Puxan N., Alemany R. Coagulation factors determine tumor transduction in vivo. Human Gene Therapy 2008, 19:1415-1419.
28. Gros A., Martinez-Quintanilla J., Puig C., Guedan S., Mollevi D.G., Alemany R., et al. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Research 2008, 68:8928-8937.
29. Guedan S., Rojas J.J., Gros A., Mercade E., Cascallo M., Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Molecular Therapy 2010, 18:1275-1283.
30. Hadac E.M., Kelly E.J., Russell S.J. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. Molecular Therapy 2011, 19:1041-1047.
31. Hamada K., Desaki J., Nakagawa K., Zhang T., Shirakawa T., Gotoh A., et al. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Molecular Therapy 2007, 15:1121-1128.
32. Khare R., Reddy V.S., Nemerow G.R., Barry M.A. Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. Journal of Virology 2012, 86:2293-2301.
33. Khoobyarian N., Barone F., Sabet T., El-Domeiri A.A., Das Gupta T.K. Inhibition of melanoma growth in hamsters by type-2 adenovirus. Journal of Surgical Oncology 1975, 7:421-425.
34. Kim J.H., Lee Y.S., Kim H., Huang J.H., Yoon A.R., Yun C.O. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. Journal of the National Cancer Institute 2006, 98:1482-1493.
35. Komarova S., Kawakami Y., Stoff-Khalili M.A., Curiel D.T., Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Molecular Cancer Therapeutics 2006, 5:755-766.
36. Koski A., Raki M., Nokisalmi P., Liikanen I., Kangasniemi L., Joensuu T., et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Molecular Therapy 2012, 20:221-229.
37. Krause A., Joh J.H., Hackett N.R., Roelvink P.W., Bruder J.T., Wickham T.J., et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. Journal of Virology 2006, 80:5523-5530.
38. Kwon O.J., Kang E., Kim S., Yun C.O. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery. Journal of Controlled Release 2011, 155:317-325.
39. Lapteva N., Aldrich M., Weksberg D., Rollins L., Goltsova T., Chen S.Y., et al. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. Journal of Immunotherapy 2009, 32:145-156.
40. Le Boeuf F., Niknejad N., Wang J., Auer R., Weberpals J.I., Bell J.C., et al. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus induced oncolysis: Potential role of human papilloma virus infection. International Journal of Cancer 2011, 134:204-215.
41. Li J.L., Liu H.L., Zhang X.R., Xu J.P., Hu W.K., Liang M., et al. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Therapy 2009, 16:376-382.
42. Lopez M.V., Viale D.L., Cafferata E.G., Bravo A.I., Carbone C., Gould D., et al. Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS One 2009, 4:e5119.
43. Luo J., Xia Q., Zhang R., Lv C., Zhang W., Wang Y., et al. Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clinical Cancer Research 2008, 14:2450-2457.
44. Martin K., Brie A., Saulnier P., Perricaudet M., Yeh P., Vigne E. Simultaneous CAR- and alpha V integrin-binding ablation fails to reduce Ad5 liver tropism. Molecular Therapy 2003, 8:485-494.
45. Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252:854-856.
46. Neesse A., Michl P., Frese K.K., Feig C., Cook N., Jacobetz M.A., et al. Stromal biology and therapy in pancreatic cancer. Gut 2010, 60:861-868.
47. Oberg D., Yanover E., Adam V., Sweeney K., Costas C., Lemoine N.R., et al. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clinical Cancer Research 2010, 16:541-553.
48. Pesonen S., Kangasniemi L., Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: Focus on translational and clinical data. Molecular Pharmaceutics 2011, 8:12-28.
49. Post D.E., Sandberg E.M., Kyle M.M., Devi N.S., Brat D.J., Xu Z., et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Research 2007, 67:6872-6881.
50. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Research 2002, 62:6070-6079.
51. Schirmbeck R., Reimann J., Kochanek S., Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Molecular Therapy 2008, 16:1609-1616.
52. Shashkova E.V., Kuppuswamy M.N., Wold W.S., Doronin K. Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Therapy 2008, 15:61-72.
53. Shiratsuchi T., Rai U., Krause A., Worgall S., Tsuji M. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. Journal of Clinical Investigation 2011, 120:3688-3701.
54. Subramanian T., Vijayalingam S., Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. Journal of Virology 2006, 80:2000-2012.
55. Thomas M.A., Spencer J.F., La Regina M.C., Dhar D., Tollefson A.E., Toth K., et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Research 2006, 66:1270-1276.
56. Tysome J., Li X., Wang S., Wang P., Gao D., Chen D., et al. Sequential use of two different oncolytic viruses: A novel therapeutic regime to eradicate established tumors with an effective induction of tumour-specific immunity. Human Gene Therapy 2011, 22:A124.
57. Van den Bossche J., Al-Jamal W.T., Yilmazer A., Bizzarri E., Tian B., Kostarelos K. Intracellular trafficking and gene expression of pH-sensitive, artificially enveloped adenoviruses in vitro and in vivo. Biomaterials 2011, 32:3085-3093.
58. Watanabe Y., Kojima T., Kagawa S., Uno F., Hashimoto Y., Kyo S., et al. A novel translational approach for human malignant pleural mesothelioma: Heparanase-assisted dual virotherapy. Oncogene 2010, 29:1145-1154.
59. Whatcott C.J., Han H., Posner R.G., Hostetter G., Von Hoff M.D. Targeting the tumor microenvironment in cancer: Why hyaluronidase deserves a second look. Cancer Discovery 2011, 1:291-296.
60. Willmon C., Harrington K., Kottke T., Prestwich R., Melcher A., Vile R. Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Molecular Therapy 2009, 17:1667-1676.
61. Witte P.L., Streilein J.W. Development and ontogeny of hamster T cell subpopulations. The Journal of Immunology 1986, 137:45-54.
62. Worgall S., Krause A., Qiu J., Joh J., Hackett N.R., Crystal R.G. Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. Journal of Virology 2007, 81:13801-13808.
63. Yan W., Kitzes G., Dormishian F., Hawkins L., Sampson-Johannes A., Watanabe J., et al. Developing novel oncolytic adenoviruses through bioselection. Journal of Virology 2003, 77:2640-2650.
64. Yong R.L., Shinojima N., Fueyo J., Gumin J., Vecil G.G., Marini F.C., et al. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Research 2009, 69:8932-8940.
65. Zheng J.N., Pei D.S., Sun F.H., Liu X.Y., Mao L.J., Zhang B.F., et al. Potent antitumor efficacy of interleukin-18 delivered by conditionally replicative adenovirus vector in renal cell carcinoma-bearing nude mice via inhibition of angiogenesis. Cancer Biology & Therapy 2009, 8:599-606.
66. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nature Reviews. Clinical Oncology 2011, 8:151-160.